News

The new drug application for Axiron is currently under regulatory review by the FDA for the treatment of testosterone deficiency (hypogonadism) in men. As per the terms of

Dove has appointed Athena as its exclusive partner for Mainland China and Hong Kong, and is expected to work together to enhance the opportunities for publishing clinical research/basic

4-Antibody is expected to use its proprietary and unencumbered Hu-PAC and Retrocyte Display technologies for the discovery and development of fully human antibodies against novel targets nominated by

Chesapeake said that the choice of press, following exhaustive trials at Komori’s Graphic Technology Centres in Japan and Holland, will be installed in June. The press has been

Icagen said that the photosensitive epilepsy study was a placebo-controlled, single blind study conducted at two clinical research centers in the US with specialised expertise in the conduct

The new capabilities of the Wave RPD System are expected to drive future growth at Celerus beyond IHC and into rapid molecular assays. Feasibility has been demonstrated for

Reportedly, both the companies are expected to shortly initiate a technical evaluation of several Microbidex product formulations for their utility against human topical fungal infections. Once the evaluation

Risedronate sodium hydrate is a bisphosphonate antiosteoporotic agent, which is currently approved in more than 90 countries. A once-monthly formulation of risedronate sodium hydrate was already approved outside

The results demonstrated that the Taxus Express Stent reduced ischemia-driven target lesion revascularization (TLR) at one year and binary in-stent restenosis at 13 months in diabetic patients experiencing